Tiziana Life Sciences to launch phase 2 trial of Foralumab in Covid-19

Tiziana Life Sciences said that it plans to launch a phase 2 clinical trial to evaluate the nasal administration of Foralumab in moderate to severe Covid-19 patients.

Foralumab is an anti-CD3 human monoclonal antibody developed by the UK-based biotech company.

Tiziana Life Sciences said that a recently held clinical study in mild to moderate Covid-19 patients gave evidence that the nasally administered antibody brought down pulmonary and systemic inflammation and was well tolerated.

The early-stage study was conducted in collaboration with scientific teams at the Harvard Medical School in Boston, US, and INTRIALS, a Latin American CRO based in Brazil.

Tiziana Life Sciences intends to undertake a phase 2 randomized, placebo-controlled trial in Brazil in moderate to severe hospitalized Covid-19 patients to assess Foralumab in a more compromised group.

All patients in the mid-stage trial will be given standard of care background therapy, said the British biotech company.

Tiziana Life Sciences to launch phase 2 trial of Foralumab in Covid-19. Image courtesy of visuals3Dde from Pixabay.

According to Tiziana Life Sciences, nasal treatment with Foralumab can modulate the immune system and help in triggering regulatory T-cells (Tregs) for the treatment of Covid-19.

Dr Neil Graham – Chief Medical Officer at Tiziana Life Sciences said: “We are  excited about this next important step in our goal to validate our drug candidate and our novel delivery system as a promising and innovative approach to immunomodulatory therapy for Covid-19 and other mutant variants.

“By focusing on moderating the inflammatory consequences of the SARS CoV2 virus, we hope to have a therapy that has efficacy irrespective of local viral variants.”